Response to ‘Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study’

Documenti analoghi

• PADI4 and HLA-DRB1 Are Genetic Risks for Radiographic Progression in RA Patients, Independent of ACPA Status: Results from the IORRA Cohort Study
  di: Suzuki, Taku, et al.
  Pubblicazione: (2013)
• Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study
  di: Bang, So-Young, et al.
  Pubblicazione: (2010)
• Peptidyl Arginine Deiminase 2 (PADI2)-Mediated Arginine Citrullination Modulates Transcription in Cancer
  di: Beato, Miguel, et al.
  Pubblicazione: (2020)
• Peptidyl Arginine Deiminases: Detection and Functional Analysis of Protein Citrullination
  di: Tilvawala, Ronak, et al.
  Pubblicazione: (2019)
• A GC polymorphism associated with serum 25-hydroxyvitamin D level is a risk factor for hip fracture in Japanese patients with rheumatoid arthritis: 10-year follow-up of the Institute of Rheumatology, Rheumatoid Arthritis cohort study
  di: Yoshida, Shinji, et al.
  Pubblicazione: (2014)